# DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With AML

> **NCT01898663** · PHASE1,PHASE2 · RECRUITING · sponsor: **Affiliated Hospital to Academy of Military Medical Sciences** · enrollment: 30 (estimated)

## Conditions studied

- High-risk Soft Tissue Sarcoma

## Interventions

- **BIOLOGICAL:** Adenovirus-transfected DC + CIK

## Key facts

- **NCT ID:** NCT01898663
- **Lead sponsor:** Affiliated Hospital to Academy of Military Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2013-06
- **Primary completion:** 2024-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01898663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01898663, "DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With AML". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01898663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*